Home > Research > Publications & Outputs > A Mendelian randomization study of circulating ...

Associated organisational unit

Electronic data

  • InterAct_MR_uric_acid_diabetes_third_revision_clean_version

    Rights statement: This is an author-created, uncopyedited electronic version of an article accepted for publication in Diabetes. The American Diabetes Association (ADA), publisher of Diabetes, is not responsible for any errors or omissions in this version of the manuscript or any version derived from it by third parties. The definitive publisher-authenticated version will be available in a future issue of Diabetes in print and online at http://diabetes.diabetesjournals.org/content/64/8/3028

    Accepted author manuscript, 330 KB, PDF document

    Available under license: CC BY: Creative Commons Attribution 4.0 International License

Links

Text available via DOI:

View graph of relations

A Mendelian randomization study of circulating uric acid and type 2 diabetes

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Published

Standard

A Mendelian randomization study of circulating uric acid and type 2 diabetes. / Sluijs, Ivonne; Holmes, Michael V.; van der Schouw, Yvonne T.; Beulens, Joline W. J.; Asselbergs, Folkert W.; Huerta, José María; Palmer, Tom M.; Arriola, Larraitz; Balkau, Beverley; Barricarte, Aurelio; Boeing, Heiner; Clavel-Chapelon, Françoise; Fagherazzi, Guy; Franks, Paul W.; Gavrila, Diana; Kaaks, Rudolf; Khaw, Kay Tee; Kühn, Tilman; Molina-Montes, Esther; Mortensen, Lotte Maxild; Nilsson, Peter M.; Overvad, Kim; Palli, Domenico; Panico, Salvatore; Quirós, J. Ramón; Rolandsson, Olov; Sacerdote, Carlotta; Sala, Núria; Schmidt, Julie A.; Scott, Robert A.; Sieri, Sabina; Slimani, Nadia; Spijkerman, Annemieke Mw; Tjonneland, Anne; Travis Dphil, Ruth C.; Tumino, Rosario; van der A, Daphne L.; Sharp, Stephen J.; Forouhi, Nita G.; Langenberg, Claudia; Riboli, Elio; Wareham, Nicholas J.; InterAct consortium.

In: Diabetes, Vol. 64, No. 8, 08.2015, p. 3028-3036.

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Harvard

Sluijs, I, Holmes, MV, van der Schouw, YT, Beulens, JWJ, Asselbergs, FW, Huerta, JM, Palmer, TM, Arriola, L, Balkau, B, Barricarte, A, Boeing, H, Clavel-Chapelon, F, Fagherazzi, G, Franks, PW, Gavrila, D, Kaaks, R, Khaw, KT, Kühn, T, Molina-Montes, E, Mortensen, LM, Nilsson, PM, Overvad, K, Palli, D, Panico, S, Quirós, JR, Rolandsson, O, Sacerdote, C, Sala, N, Schmidt, JA, Scott, RA, Sieri, S, Slimani, N, Spijkerman, AM, Tjonneland, A, Travis Dphil, RC, Tumino, R, van der A, DL, Sharp, SJ, Forouhi, NG, Langenberg, C, Riboli, E, Wareham, NJ & InterAct consortium 2015, 'A Mendelian randomization study of circulating uric acid and type 2 diabetes', Diabetes, vol. 64, no. 8, pp. 3028-3036. https://doi.org/10.2337/db14-0742

APA

Sluijs, I., Holmes, M. V., van der Schouw, Y. T., Beulens, J. W. J., Asselbergs, F. W., Huerta, J. M., Palmer, T. M., Arriola, L., Balkau, B., Barricarte, A., Boeing, H., Clavel-Chapelon, F., Fagherazzi, G., Franks, P. W., Gavrila, D., Kaaks, R., Khaw, K. T., Kühn, T., Molina-Montes, E., ... InterAct consortium (2015). A Mendelian randomization study of circulating uric acid and type 2 diabetes. Diabetes, 64(8), 3028-3036. https://doi.org/10.2337/db14-0742

Vancouver

Sluijs I, Holmes MV, van der Schouw YT, Beulens JWJ, Asselbergs FW, Huerta JM et al. A Mendelian randomization study of circulating uric acid and type 2 diabetes. Diabetes. 2015 Aug;64(8):3028-3036. https://doi.org/10.2337/db14-0742

Author

Sluijs, Ivonne ; Holmes, Michael V. ; van der Schouw, Yvonne T. ; Beulens, Joline W. J. ; Asselbergs, Folkert W. ; Huerta, José María ; Palmer, Tom M. ; Arriola, Larraitz ; Balkau, Beverley ; Barricarte, Aurelio ; Boeing, Heiner ; Clavel-Chapelon, Françoise ; Fagherazzi, Guy ; Franks, Paul W. ; Gavrila, Diana ; Kaaks, Rudolf ; Khaw, Kay Tee ; Kühn, Tilman ; Molina-Montes, Esther ; Mortensen, Lotte Maxild ; Nilsson, Peter M. ; Overvad, Kim ; Palli, Domenico ; Panico, Salvatore ; Quirós, J. Ramón ; Rolandsson, Olov ; Sacerdote, Carlotta ; Sala, Núria ; Schmidt, Julie A. ; Scott, Robert A. ; Sieri, Sabina ; Slimani, Nadia ; Spijkerman, Annemieke Mw ; Tjonneland, Anne ; Travis Dphil, Ruth C. ; Tumino, Rosario ; van der A, Daphne L. ; Sharp, Stephen J. ; Forouhi, Nita G. ; Langenberg, Claudia ; Riboli, Elio ; Wareham, Nicholas J. ; InterAct consortium. / A Mendelian randomization study of circulating uric acid and type 2 diabetes. In: Diabetes. 2015 ; Vol. 64, No. 8. pp. 3028-3036.

Bibtex

@article{f092618587334884b6ae72eb9280af3c,
title = "A Mendelian randomization study of circulating uric acid and type 2 diabetes",
abstract = "We aimed to investigate the causal effect of circulating uric acid concentrations on type 2 diabetes risk. A Mendelian randomization study was performed using a genetic score with 24 uric acid associated loci. We used data of the EPIC-InterAct case-cohort study, comprising 24,265 individuals of European ancestry from eight European countries. During a mean (SD) follow-up of 10 (4) years, 10,576 verified incident type 2 diabetes cases were ascertained. Higher uric acid associated with higher diabetes risk following adjustment for confounders, with a HR of 1.20 (95%CI: 1.11,1.30) per 59.48 µmol/L (1 mg/dL) uric acid. The genetic score raised uric acid by 17 µmol/L (95%CI: 15,18) per SD increase, and explained 4% of uric acid variation. Using the genetic score to estimate the unconfounded effect found that a 59.48 µmol/L higher uric acid concentration did not have a causal effect on diabetes (HR 1.01, 95%CI: 0.87,1.16). Including data from DIAGRAM consortium, increasing our dataset to 41,508 diabetes cases, the summary OR estimate was 0.99 (95%CI: 0.92, 1.06). In conclusion, our study does not support a causal effect of circulating uric acid on diabetes risk. Uric acid lowering therapies may therefore not be beneficial in reducing diabetes risk.",
author = "Ivonne Sluijs and Holmes, {Michael V.} and {van der Schouw}, {Yvonne T.} and Beulens, {Joline W. J.} and Asselbergs, {Folkert W.} and Huerta, {Jos{\'e} Mar{\'i}a} and Palmer, {Tom M.} and Larraitz Arriola and Beverley Balkau and Aurelio Barricarte and Heiner Boeing and Fran{\c c}oise Clavel-Chapelon and Guy Fagherazzi and Franks, {Paul W.} and Diana Gavrila and Rudolf Kaaks and Khaw, {Kay Tee} and Tilman K{\"u}hn and Esther Molina-Montes and Mortensen, {Lotte Maxild} and Nilsson, {Peter M.} and Kim Overvad and Domenico Palli and Salvatore Panico and Quir{\'o}s, {J. Ram{\'o}n} and Olov Rolandsson and Carlotta Sacerdote and N{\'u}ria Sala and Schmidt, {Julie A.} and Scott, {Robert A.} and Sabina Sieri and Nadia Slimani and Spijkerman, {Annemieke Mw} and Anne Tjonneland and {Travis Dphil}, {Ruth C.} and Rosario Tumino and {van der A}, {Daphne L.} and Sharp, {Stephen J.} and Forouhi, {Nita G.} and Claudia Langenberg and Elio Riboli and Wareham, {Nicholas J.} and {InterAct consortium}",
note = "This is an author-created, uncopyedited electronic version of an article accepted for publication in Diabetes. The American Diabetes Association (ADA), publisher of Diabetes, is not responsible for any errors or omissions in this version of the manuscript or any version derived from it by third parties. The definitive publisher-authenticated version will be available in a future issue of Diabetes in print and online at http://diabetes.diabetesjournals.org/content/64/8/3028",
year = "2015",
month = aug,
doi = "10.2337/db14-0742",
language = "English",
volume = "64",
pages = "3028--3036",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "8",

}

RIS

TY - JOUR

T1 - A Mendelian randomization study of circulating uric acid and type 2 diabetes

AU - Sluijs, Ivonne

AU - Holmes, Michael V.

AU - van der Schouw, Yvonne T.

AU - Beulens, Joline W. J.

AU - Asselbergs, Folkert W.

AU - Huerta, José María

AU - Palmer, Tom M.

AU - Arriola, Larraitz

AU - Balkau, Beverley

AU - Barricarte, Aurelio

AU - Boeing, Heiner

AU - Clavel-Chapelon, Françoise

AU - Fagherazzi, Guy

AU - Franks, Paul W.

AU - Gavrila, Diana

AU - Kaaks, Rudolf

AU - Khaw, Kay Tee

AU - Kühn, Tilman

AU - Molina-Montes, Esther

AU - Mortensen, Lotte Maxild

AU - Nilsson, Peter M.

AU - Overvad, Kim

AU - Palli, Domenico

AU - Panico, Salvatore

AU - Quirós, J. Ramón

AU - Rolandsson, Olov

AU - Sacerdote, Carlotta

AU - Sala, Núria

AU - Schmidt, Julie A.

AU - Scott, Robert A.

AU - Sieri, Sabina

AU - Slimani, Nadia

AU - Spijkerman, Annemieke Mw

AU - Tjonneland, Anne

AU - Travis Dphil, Ruth C.

AU - Tumino, Rosario

AU - van der A, Daphne L.

AU - Sharp, Stephen J.

AU - Forouhi, Nita G.

AU - Langenberg, Claudia

AU - Riboli, Elio

AU - Wareham, Nicholas J.

AU - InterAct consortium

N1 - This is an author-created, uncopyedited electronic version of an article accepted for publication in Diabetes. The American Diabetes Association (ADA), publisher of Diabetes, is not responsible for any errors or omissions in this version of the manuscript or any version derived from it by third parties. The definitive publisher-authenticated version will be available in a future issue of Diabetes in print and online at http://diabetes.diabetesjournals.org/content/64/8/3028

PY - 2015/8

Y1 - 2015/8

N2 - We aimed to investigate the causal effect of circulating uric acid concentrations on type 2 diabetes risk. A Mendelian randomization study was performed using a genetic score with 24 uric acid associated loci. We used data of the EPIC-InterAct case-cohort study, comprising 24,265 individuals of European ancestry from eight European countries. During a mean (SD) follow-up of 10 (4) years, 10,576 verified incident type 2 diabetes cases were ascertained. Higher uric acid associated with higher diabetes risk following adjustment for confounders, with a HR of 1.20 (95%CI: 1.11,1.30) per 59.48 µmol/L (1 mg/dL) uric acid. The genetic score raised uric acid by 17 µmol/L (95%CI: 15,18) per SD increase, and explained 4% of uric acid variation. Using the genetic score to estimate the unconfounded effect found that a 59.48 µmol/L higher uric acid concentration did not have a causal effect on diabetes (HR 1.01, 95%CI: 0.87,1.16). Including data from DIAGRAM consortium, increasing our dataset to 41,508 diabetes cases, the summary OR estimate was 0.99 (95%CI: 0.92, 1.06). In conclusion, our study does not support a causal effect of circulating uric acid on diabetes risk. Uric acid lowering therapies may therefore not be beneficial in reducing diabetes risk.

AB - We aimed to investigate the causal effect of circulating uric acid concentrations on type 2 diabetes risk. A Mendelian randomization study was performed using a genetic score with 24 uric acid associated loci. We used data of the EPIC-InterAct case-cohort study, comprising 24,265 individuals of European ancestry from eight European countries. During a mean (SD) follow-up of 10 (4) years, 10,576 verified incident type 2 diabetes cases were ascertained. Higher uric acid associated with higher diabetes risk following adjustment for confounders, with a HR of 1.20 (95%CI: 1.11,1.30) per 59.48 µmol/L (1 mg/dL) uric acid. The genetic score raised uric acid by 17 µmol/L (95%CI: 15,18) per SD increase, and explained 4% of uric acid variation. Using the genetic score to estimate the unconfounded effect found that a 59.48 µmol/L higher uric acid concentration did not have a causal effect on diabetes (HR 1.01, 95%CI: 0.87,1.16). Including data from DIAGRAM consortium, increasing our dataset to 41,508 diabetes cases, the summary OR estimate was 0.99 (95%CI: 0.92, 1.06). In conclusion, our study does not support a causal effect of circulating uric acid on diabetes risk. Uric acid lowering therapies may therefore not be beneficial in reducing diabetes risk.

U2 - 10.2337/db14-0742

DO - 10.2337/db14-0742

M3 - Journal article

C2 - 25918230

VL - 64

SP - 3028

EP - 3036

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 8

ER -